LXRX · XBRL financial data

Lexicon Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (LXRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	0	year only	1	2	2	year only	1	29	14	5*	21	1
Revenue from contracts with customers	0	year only	1	2	2	2*	1	—	—	—	—	—
Cost of goods and services sold	0	year only	0	0	0	year only	0	0	0	0*	0	0
Research and development	18	15*	14	18	26	27*	15	16	19	11*	13	17
Selling, general and administrative	32	33*	32	39	40	32*	12	9	8	9*	9	10
Operating income (loss)	(50)	(47)*	(45)	(55)	(64)	(33)*	(26)	4	(12)	(15)*	(1)	(27)
Interest expense	4	—	—	—	—	—	—	—	—	—	—	—
Other income (expense)	3	2*	2	4	3	3*	2	2	2	1*	2	2
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	—	—	—
Net income (loss)	(51)	(50)*	(48)	(53)	(65)	(34)*	(25)	3	(13)	(16)*	(1)	(32)
Earnings per share, basic USD per share	(0.21)	(0.20)*	(0.20)	(0.17)	(0.18)	(0.09)*	(0.07)	0.01	(0.04)	(0.04)*	0.00	(0.07)
Earnings per share, diluted USD per share	(0.21)	(0.20)*	(0.20)	(0.17)	(0.18)	(0.09)*	(0.07)	0.01	(0.04)	(0.04)*	0.00	(0.07)
Weighted average shares, basic millions of shares	245	245*	245	311	361	361*	362	363	363	363*	400	438
Weighted average shares, diluted millions of shares	245	245*	245	311	361	361*	362	364	363	363*	400	438

Fiscal quarters (LXRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	21	22	96	36	35	67	63	21	50	34	38	41
Short-term investments	197	148	259	274	224	171	132	118	66	62	133	150
Marketable securities	197	148	259	274	224	171	132	118	66	62	133	150
Accounts receivable	0	1	2	3	3	3	47	2	2	2	12	2
Inventory	0	0	1	1	1	0	0	0	0	0	0	1
Total current assets	223	177	365	321	269	246	246	145	123	102	186	197
Property and equipment, net	2	2	2	2	2	2	2	2	2	2	2	2
Right-of-use asset	6	6	5	5	5	5	5	4	8	7	7	7
Goodwill	45	45	45	45	45	45	45	45	45	45	45	45
Total assets	276	229	417	373	321	298	298	226	206	185	269	250
Accounts payable	12	14	8	12	14	15	11	6	4	3	3	2
Accrued liabilities	20	17	15	16	22	30	13	11	14	13	7	12
Current portion of long-term debt	—	—	—	—	—	0	42	—	—	5	0	0
Total current liabilities	32	32	23	28	36	45	111	35	22	21	10	15
Long-term debt	99	100	100	99	100	100	59	56	57	49	50	51
Lease liability, non-current	5	5	5	5	5	5	5	4	7	7	6	6
Total liabilities	137	136	128	133	143	152	175	96	86	77	66	76
Accumulated deficit	(1,717)	(1,767)	(1,815)	(1,869)	(1,933)	(1,967)	(1,993)	(1,989)	(2,002)	(2,018)	(2,019)	(2,050)
Total stockholders' equity	140	93	289	240	179	146	123	129	120	108	203	175
Total liabilities and equity	276	229	417	373	321	298	298	226	206	185	269	250
Common shares outstanding (cover page) millions of shares	245	246	246	361	361	361	363	363	363	424	444	445

Fiscal quarters (LXRX's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(51)	(50)*	(48)	(53)	(65)	(34)*	(25)	3	(13)	(16)*	(1)	(32)
Stock-based compensation	4*	3*	4	5*	3*	2*	3	3*	3*	3*	3	3*
Depreciation and amortization	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from operating activities	(42)*	(51)*	(55)	(49)*	(54)*	(21)*	(44)	17*	(24)*	(17)*	(15)	(9)*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	—	—	0*	0*	—	—
Net cash from investing activities	(39)*	52*	(110)	(12)*	53*	54*	41	15*	52*	5*	(70)	(16)*
Proceeds from issuing common stock	(0)*	0*	0	(0)*	0*	0*	0	0*	—	year only	70	1*
Share repurchases	0*	0*	2	0*	0*	0*	—	—	—	—	—	—
Proceeds from long-term debt	0*	(0)*	—	—	0*	0*	—	—	—	year only	—	—
Net cash from financing activities	(0)*	(0)*	239	(0)*	(1)*	(0)*	(1)	(45)*	0*	(3)*	89	(1)*
Net change in cash	(81)*	1*	74	(61)*	(1)*	32*	(4)	(13)*	28*	(15)*	4	(26)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Lexicon Pharmaceuticals	41	0.7	(9.2)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	86	12	6.1	12.5M	—	Q1 FY26 10-QMar 31, 2026
Omeros	2	29	4.1*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Astria Therapeutics	96	0.7	(32)*	57.1M	7.1 quarters	Q3 FY25 10-QSep 30, 2025
4D Molecular Therapeutics	70	3.8	(70)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Crescent Biopharma	172	0	(19)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37	1.1	(7.2)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	50	not reported	(23)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	53	0*	(3.2)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.